# Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
Canonical URL: https://biopharmsignal.com/news/HRTX/heron-therapeutics-to-report-second-quarter-2026-financial-results-on-monday-aug-c850c6e7
Ticker: HRTX
Company: Heron Therapeutics
Source: Heron Therapeutics
Published: 2026-07-27 12:30 EST
## Summary

Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology...

## Article Body
Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights.

The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron’s website at www.herontx.com . An archive of the teleconference and webcast will also be made available on Heron’s website for 60 days following the call.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com .

Forward-looking Statements

This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. iduarte@herontx.com 858-251-4400
## Recent Company News
- 2026-07-27 12:30 EST — [Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026](https://biopharmsignal.com/news/HRTX/heron-therapeutics-to-report-second-quarter-2026-financial-results-on-monday-aug-c850c6e7) — Source: Heron Therapeutics
- 2026-06-02 12:12 EST — [U.S. District Court Issues Decision Regarding CINVANTI® Patents](https://biopharmsignal.com/news/HRTX/u-s-district-court-issues-decision-regarding-cinvanti-patents-21c1ecf3) — Source: Heron Therapeutics
- 2026-05-11 12:00 EST — [Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance](https://biopharmsignal.com/news/HRTX/heron-therapeutics-announces-first-quarter-2026-financial-results-and-reaffirms--bde6d661) — Source: Heron Therapeutics
- 2026-04-27 21:30 EST — [Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026](https://biopharmsignal.com/news/HRTX/heron-therapeutics-to-report-first-quarter-2026-financial-results-on-monday-may--8ba7e861) — Source: Heron Therapeutics
- 2026-02-26 13:00 EST — [Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results](https://biopharmsignal.com/news/HRTX/heron-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-0c27bf55) — Source: Heron Therapeutics
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)